



# Group interim management report as at 30 June 2019

## Table of content

Group interim management report as at 30 June 2019	4
IFRS-group financial interim statement as at 30 June 2019	10
Consolidated notes as at 30 June 2019	18
Shares	26
Imprint	30

<b>An overview of the Group's financial information</b>	01/01/2019 – 30/06/2019 EUR	01/01/2018 – 30/06/2018 EUR
<b>Revenue</b>	<b>228,506,208</b>	<b>144,715,700</b>
Change in stocks of finished goods	21,409	-20,311
Other work performed by entity and capitalised	423,067	235,739
Other income	229,628	96,075
Cost of materials	213,977,466	135,019,448
Personnel expenses	4,882,195	4,549,158
Other expenses	3,250,830	2,160,406
<b>Earnings before interest, tax, depreciation and amortisation (EBITDA)</b>	<b>7,069,822</b>	<b>3,298,191</b>
Depreciation and amortisation	1,104,230	360,113
<b>Operating profit/loss (EBIT)</b>	<b>5,965,591</b>	<b>2,938,079</b>
Financial expenses	69,814	17,422
Financial income	5,059	6,947
<b>Earnings before taxes (EBT)</b>	<b>5,900,836</b>	<b>2,927,604</b>
Income taxes	1,929,427	1,401,373
<b>Consolidated earnings after tax</b>	<b>3,971,409</b>	<b>1,526,232</b>
<b>Total consolidated earnings</b>	<b>3,971,409</b>	<b>1,526,232</b>
<b>Special effects</b>		
Personnel expenses for the share option programme	642,044	1,150,417
Amortisations of the customer base	303,760	50,627
One-off special expenses for the commissioning of the laboratories acquired in September 2017		643,993
<b>Earnings before amortisations (EBITDA) adjusted for special effects</b>	<b>7,711,865</b>	<b>5,043,959</b>
Change compared with the previous year	53%	
<b>Earnings before taxes (EBT) adjusted for special effects</b>	<b>6,846,640</b>	<b>4,772,641</b>
Change compared with the previous year	43%	
<b>Earnings per share</b>	<b>EUR 2019</b>	<b>EUR 2018</b>
Undiluted earnings per share (in EUR)	0,27	0,11
Diluted earnings per share (in EUR)	0,27	0,11

# Group interim management report as at 30 June 2019

## Macroeconomic situation and environment

According to the Federal Ministry for Economic Affairs and Energy (Bundesministerium für Wirtschaft und Energie – BMWi), the German economy continues to be on a course for growth for the tenth year in a row. However, the economy is still growing rather sluggishly after a surprisingly strong first quarter in 2019. Gross domestic product increased in the first quarter by 0.4%, meaning that the BMWi only expects growth of 0.5% for the entire year. Even if manufacturing industries increased production slightly by 0.3% in May, the trend is overall on the decline. The reasons for this can be seen in the persistently high risks such as trade disputes arising from the US which encumber the German export economy in particular. Brexit must also be seen as a risk factor. The danger of a “hard” Brexit is still in the air.

Private consumption is expected to decrease compared with the previous quarter with growth of 1.2% after a strong first quarter. The retail sales and first-time car registration indicators point towards an overall decline in private consumption despite disposable income increasing by 3.2% (source: Destatis).

## Significant events in the first half of 2019

As a result of the private placement on 26 February 2019, Medios AG's free float increased to 56.1%. Its core shareholder, Manfred Schneider (under attribution of Tangaroa Management GmbH [previously mediosmanagement GmbH]), sold approximately 15% of the share capital and currently holds 40.5%.

The four BerlinApotheke were renamed as MediosApotheke on 1 March 2019. MediosApotheke remains an independent company with Anike Oleski as the sole shareholder. Its focus on quality and expertise in the area of speciality pharmaceuticals is practically unrivalled in Germany. Medios would like to create uniform quality standards through this partnership that are immediately visible and advantageous to patients via the Medios brand. How MediosApotheke appears in public will also contribute to increasing the visibility of Medios as a leading provider of speciality pharmaceutical solutions.

On 23 April 2019, the Management Board increased the sales forecast for the 2019 financial year from EUR 400m-EUR 410m to EUR 430m-EUR 440m. In addition, it increased the forecast for the adjusted EBITDA from EUR 16m-EUR 17m to EUR 16.5-EUR 17.5m and the forecast for the adjusted EBT from EUR 14m-EUR 15m to EUR 14.5-EUR 15.5m.

EBITDA and EBT are both adjusted by special expenses for share options of EUR 1.28m (with no effect on liquidity). EBT is also adjusted by the special expenses for amortisations on the customer base as a result of taking over the operating parts of BerlinApotheke Schneider & Oleski oHG of EUR 0.60m (with no effect on liquidity).

The office building in Stieffring was sold on 5 June 2019. Its transfer of use is planned for September 2019, meaning that the proceeds from the sale could not be considered in this halfyearly report. The sale price is EUR 4.22m. After deducting all costs, the net profit from the sale is EUR 0.8m.

The management activities of Medios companies are being combined as planned by renting new office space in Berlin-Mitte. Completion and transfer is planned for February 2020.

The founding of Medios Analytics and a planned spin-off of a partial business operation on 1 July 2019 will lead to the creation of a new business area offering innovative measurement, verification and certification methods. These activities were previously carried out under the umbrella of Medios Manufaktur. With its own business premises in Potsdam, the business area will have the necessary opportunities to develop into another pillar of the Medios Group in future.

On 16 July 2019, Medios gained an Austrian ‘Family Office’ as an investor. The Family Office, the name of which shall remain confidential, as agreed, acquired a share package of 100,000 shares. The shares acquired in the share package were serviced via share options by management and members of the Management Board. They had been guaranteed in the 2016 financial year as part of an employee investment plan.

## Earnings, financial and net asset position

The earnings position of the Medios Group continued to improve in the first half of 2019 compared to the same period of the previous year.

The Medios Group generated turnover of EUR 228m, which was slightly above expectations. Turnover increased by EUR 82.2m or 57.9% in comparison to the previous year's period (EUR 145m).

The biggest driver of growth continued to be the Drug Supply segment which was able to increase its turnover compared with the comparison period by EUR 79.6m, or 59.0%, to EUR 215m.



The Patient-Specific Therapies segment also continued to increase in comparison to the previous year. The discontinuation of tenders for oncological applications which made up the lion's share of turnover in the previous year could be more than offset by turnover in the area of non-cytostatic preparations. Turnover increased by EUR 2.52m to EUR 28.7m (previous year's period: EUR 26.2m). This is equivalent to growth of 9.6%.

Turnover in the Services segment increased slightly by EUR 0.80m to EUR 2.01m. The segment provides services within the Group, in particular in the areas of IT and finance. Sales with third parties are generated through IT services provided to pharmacies.

All revenue was generated almost exclusively within Germany.

According to sales growth, the number of pharmacies supplied increased to 180.

**Material expenses** in the first half of 2019 amounted to EUR 214 million (same period of previous year: EUR 135m) or 93.6% of turnover (same period of previous year: 93.3%), therefore remaining more or less stable. Due to growth, **personnel costs** increased by EUR 0.33m to EUR 4.88m (including special expenses for share options of EUR 0.64m which had no effect on liquidity). **Other expenses** amounted to EUR 3.25m after EUR 2.16m in the first half of 2018. The reason for this in particular was the variable cost increases in sales for packaging and shipping, but also increased transportation and advertising costs.

Accordingly, **EBITDA before special effects** recorded an increase. It rose by EUR 2.68m or 52.9% to EUR 7.71m. This amounted to EUR 5.04m in the previous year's period.

EBT before special effects climbed from EUR 4.72m to EUR 6.85m, an increase of 45% in a year-on-year comparison.

Whilst EBITDA before special effects increased in the Drug Supply segment disproportionately by EUR 0.76m or 16.6% to EUR 5.36m, EBITDA before special effects in the Patient-Specific Therapies segment increased by EUR 1.79m to EUR 2.80m. This is equivalent to growth of 177%.

As a result of the increasingly expense-based passing on of internal services to the subsidiaries of the Medios Group, the Services segment recorded EBITDA before special effects of EUR -0.44m. This was EUR -0.54m in the same period in the previous year.

Special effects of EUR 0.64m resulted from share options and the amortisation of the customer base capitalised in 2018 as a result of taking over the operating sections of Berlin-Apotheke Schneider & Oleski oHG of EUR 0.30m.

Operating **cash flow** increased considerably by EUR 1.90 million to EUR 1.08 million, meaning it was positive for the first time. The crucial contributing factor was the increase in profit in the first half of 2019 by EUR 2.45m.

As a result of the change in the recording of expenses from operating leasing arrangements in the cash flow statement, there was an improvement in operating cash flow of EUR 0.26m in the first half of 2019. The net cash outflow from financing activities decreased accordingly.

Expenses with no effect on payment such as amortisation and the increase in provisions amounted to EUR 0.97m. This amounted to EUR -0.08m in the previous year. Other expenses with no effect on payment of EUR 0.64m are a result of the share options granted to employees. This was EUR 1.15m in the previous year.

The high increase in receivables and inventories in comparison to the previous year led to a cash outflow of EUR 11.8m in the reporting period. This amounted to EUR 9.08m in the first half of 2018. The majority resulted from the increase in trade receivables due to growth, whilst inventories even slightly decreased in the first half of 2019.

There was a cash inflow of EUR 4.83m from the increase in liabilities from trade payables and other liabilities that cannot be attributed to investment or financing activity. This was EUR 6.27m in the same period in the previous year. This development can be attributed in particular to liabilities from trade payables. Growth in sales resulted in an increase in the consumption of materials and, by association, liabilities.

Income tax expenses amounted to EUR 2.35m, i.e. EUR 0.95m more than in the same period of the previous year.

As no income tax has been paid in 2019 and the income tax receivables from 2018 were offset, there were no cash flows from income taxes, the reason being the profit transfer agreements concluded in 2018. In contrast, there was a cash outflow of EUR 2m in the comparison period.

EUR 1.02m were used to acquire assets for cash flow for investments, EUR 0.32m more than in the same period of the previous year.



**MEDIOS AG**  
SPECIALTY PHARMA SOLUTIONS

**Specialising in patients with chronic and/or rare diseases for whom therapy can be lengthy and costly.**

PHARMACEUTICAL SUPPLY	PATIENT-SPECIFIC MANUFACTURING	DRUG SAFETY
		
		
<p>Competence partner for specialty pharmaceuticals</p>	<p>Competence partner for patient-specific medicines: Cytostatic drugs, parenteral nutrition, Antibodies, clinical studies, antibiosis</p>	<p>Competence partner for GMP pharmaceutical safety</p>

Due to the new method of accounting for leases according to IFRS 16 and in connection with such leasing arrangements, pending payments are to be recorded in cash flow from financing activities. Interests of EUR 0.04m were used for this purpose and EUR 0.26m on liabilities as a lessee was paid in the first half year of 2019. EUR 0.03m were paid in bank interests. This amounted to EUR 0.07m in the same period of the previous year.

In total, cash as at 30 June 2019 decreased compared with the end of 2018 by EUR 0.27m to EUR 11.5m. Viewed on an annual basis, i.e. in comparison with 30 June 2018, cash decreased by EUR 3.65m.

The Medios Group's assets break down as follows: The balance sheet total at the end of June 2019 increased compared to 2018 financial statements by EUR 13.3m, now amounting to EUR 112m (previous year: EUR 98.4m). The increase in the balance sheet total is based on the first-time application of lease accounting according to IFRS 16 which led to an increase in assets of EUR 2.03m on the assets side. The liabilities side increased accordingly by lease liabilities. Overall, non-current assets increased by EUR 2.27m.

The increase in trade receivables by a further EUR 13.1m to EUR 44.2m is due to sales growth. Payment targets were not increased. Inventories fell by EUR 0.79m to EUR 13.2m as a result of the high turnover of stock. Other receivables increased by EUR 0.56m. Cash reduced by EUR 0.27m to EUR 11.5m compared with 31 December 2018.

Equity increased in line with the period result of EUR 3.97m and the share options used in equity of EUR 0.64m increased by EUR 4.61m to EUR 75.1m.

Liabilities from trade payables increased as a result of an increase in sales and the associated higher consumption of materials by EUR 4.21m to EUR 23.0m. Income tax liabilities increased by EUR 2.29m to EUR 4.55m and other liabilities, mainly consisting of sales tax liabilities, increased by EUR 0.82m to EUR 2.89m.

The equity ratio fell as expected as at 30 June 2019 as a result of the recognition of lease liabilities and rights of use from 71.6% to 67.2%.

### Employees

As at 30 June 2019, the Medios Group employed a total of 171 employees (previous year: 135). The number of employees increased by 36 compared with 30 June 2018 as a result of the Group's organic growth.

### Events after the balance sheet date

Medios AG successfully held the Annual General Meeting 2019 on 10 July 2019. All resolutions on the agenda items were passed with a clear majority. Overall, around 64% of the share capital was represented. Among the items on the agenda were the discharge of the members of the Management and Supervisory Boards, the choice of auditor as well as the creation of new authorised and new conditional capital for 2019. In addition, shareholders approved a profit and loss transfer agreement with Medios Analytics GmbH. The individual voting results for the agenda items are available on the website of Medios AG.

### Outlook

The Management Board expects that the upper end of the target range forecast for sales will at least be achieved for the 2019 financial year. This is equal to EUR 430m to EUR 440m. In addition, it still expects adjusted EBITDA\* of EUR 16.5m to EUR 17.5m and an adjusted EBT\* of EUR 14.5m to EUR 15.5m. Statutory amendments and additional growth investments are taken into account, provided they can be foreseen, in the forecasts.

EBITDA\* and EBT\* are both adjusted by special expenses for share options of EUR 1.28m (with no effect on liquidity). EBT is also adjusted by the special expenses for amortisations on the customer base as a result of taking over the operating sections of BerlinApotheke Schneider & Oleski oHG of EUR 0.6m (with no effect on liquidity).

### Opportunities and Risk Report

There are no findings available to the company that would result in a change in the statements made in the last Group Management Report on the Group's performance for the 2019 financial year. The statements made in the 2018 Annual Report on the opportunities and risks of the business model remain unchanged for the remainder of the 2019 financial year.

Berlin, August 2019

**Medios AG**  
**The Management Board**

# IFRS-group financial interim statement as at 30 June 2019

## Statement of comprehensive income from 01/01/2019 to 30/06/2019

	30/06/2019 EUR	30/06/2018 EUR
<b>Revenue</b>	<b>228,506,208</b>	<b>144,715,700</b>
Changes in inventories of finished goods and work in progress	21,409	-20,311
Other work performed by entity and capitalised	423,067	235,739
Other income	229,628	96,075
Cost of materials	213,977,466	135,019,448
Personnel expenses	4,882,195	4,549,158
Other expenses	3,250,830	2,160,406
<b>Earnings before interest, tax, depreciation and amortisation (EBITDA)</b>	<b>7,069,822</b>	<b>3,298,191</b>
Depreciation and amortisation	1,104,230	360,113
<b>Operating profit/loss (EBIT)</b>	<b>5,965,591</b>	<b>2,938,079</b>
Financial expenses	69,814	17,422
Financial income	5,059	6,947
<b>Earnings before taxes (EBT)</b>	<b>5,900,836</b>	<b>2,927,604</b>
Income taxes	1,929,427	1,401,373
<b>Consolidated earnings after tax</b>	<b>3,971,409</b>	<b>-6,947</b>
<b>Total consolidated earnings</b>	<b>3,971,409</b>	<b>1,526,232</b>

Consolidated balance sheet as at 30/06/2019  
Medios AG, Berlin

	30/06/2019 EUR	31/12/2018 EUR
<b>ASSETS</b>		
<b>Non-current assets</b>	<b>39,626,277</b>	<b>37,356,263</b>
Property, plant and equipment	5,767,466	5,641,252
Rights of use as a lessee	2,028,925	
Intangible assets	31,729,886	31,615,011
Financial assets	100,000	100,000
<b>Current assets</b>	<b>72,113,709</b>	<b>61,060,555</b>
Inventories	13,162,733	13,953,312
Trade receivables	44,179,439	31,074,231
Other receivables	3,272,548	3,836,600
Income tax receivables	0	424,482
Cash and cash equivalents	11,498,989	11,771,930
<b>Balance sheet total</b>	<b>111,739,986</b>	<b>98,416,818</b>

Consolidated balance sheet as at 30/06/2019  
Medios AG, Berlin

	30/06/2019 EUR	31/12/2018 EUR
<b>LIABILITIES</b>		
<b>Equity</b>	<b>75,111,135</b>	<b>70,497,682</b>
Subscribed capital	14,564,019	14,564,019
Capital reserves	50,546,407	49,904,363
Retained earnings	739,316	739,316
Profit carried forward	5,289,984	963,140
Comprehensive income	3,971,409	4,326,844
<b>Attributable to shareholders in the parent company</b>	<b>75,111,135</b>	<b>70,497,682</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>	<b>3,844,131</b>	<b>4,207,794</b>
Deferred tax liabilities	3,844,131	4,207,794
<b>Current liabilities</b>	<b>32,784,721</b>	<b>23,711,343</b>
Other provisions	243,750	374,557
Liabilities from trade receivables	23,019,652	18,807,191
Financial liabilities	0	203,169
Income tax liabilities	4,550,072	22,261,367
Liabilities as a lessee	2,083,448	
Other liabilities	2,887,798	2,065,058
<b>Total liabilities</b>	<b>36,628,851</b>	<b>27,919,137</b>
<b>Balance sheet total</b>	<b>111,739,986</b>	<b>98,416,818</b>

**Cash flow from operating activities**  
from 01/01/2019 to 30/06/2019  
Medios AG, Berlin

	01/01/2019 – 30/06/2019 KEUR	01/01/2018 – 30/06/2018 KEUR
<b>Cash flow from operating activities</b>		
Net income for the year	3,971	1,526
Depreciation and amortisation on non-current assets	1,104	360
Increase in provisions	-131	-443
Other non-cash expenses/income	642	1,150
Increase in inventories, trade receivables and other assets not at-tributable to investment or financing activities	-11,751	-9,081
Increase in liabilities from trade payables and other liabilities not attributable to investment or financing activities	4,832	6,272
Interest expenses/interest income	65	10
Income tax costs	2,350	1,401
Income tax payments	0	-2,008
<b>Net cash inflow/outflow from operating activities</b>	<b>1,083</b>	<b>-813</b>
<b>Cash flow from investment activities</b>		
Payments made for investments in intangible assets	-115	-485
Payments made for investments in property, plant and equipment	-914	-224
Interest received	5	7
<b>Cash flow from investment activities</b>	<b>-1,024</b>	<b>-702</b>
<b>Cash flow from financing activities</b>		
Interest paid	-70	-17
Payments for lease liabilities	-262	0
<b>Net cash inflow/outflow from financing activities</b>	<b>-331</b>	<b>-17</b>
Net increase in cash	-273	-1,532
Cash and cash equivalents at the beginning of the financial year at the start of the period	11,772	16,685
<b>Cash and cash equivalents at the end of the financial year</b>	<b>11,499</b>	<b>15,153</b>



## Changes in shareholders' equity as at 30/06/2018

Medios AG, Berlin

<b>As at 01/01/2019</b>
Total consolidated earnings 2018
Benefits for employees settled with equity
<b>As at 30/06/2019</b>
<b>As at 01/01/2018</b>
Net profit for the first half of 2018
Reserve for benefits settled with equity
<b>As at 30/06/2018</b>

	Subscribed capital	Capital reserve	Retained earnings	Attributable to shareholders in the parent company	Equity
	KEUR	KEUR	KEUR	KEUR	KEUR
<b>As at 01/01/2019</b>	<b>14,564,019</b>	<b>49,904,363</b>	<b>6,029,300</b>	<b>70,497,682</b>	<b>70,497,682</b>
Total consolidated earnings 2018	0	0	3,971,409	3,971,409	3,971,409
Benefits for employees settled with equity	0	642,044	0	642,044	642,044
<b>As at 30/06/2019</b>	<b>14,564,019</b>	<b>50,546,407</b>	<b>10,000,709</b>	<b>75,111,135</b>	<b>75,111,135</b>
<b>As at 01/01/2018</b>	<b>13,664,019</b>	<b>30,310,059</b>	<b>1,702,455</b>	<b>45,676,533</b>	<b>45,676,533</b>
Net profit for the first half of 2018	0	0	1,526,232	1,526,232	1,526,232
Reserve for benefits settled with equity	0	1,150,417	0	1,150,427	1,150,427
<b>As at 30/06/2018</b>	<b>13,664,019</b>	<b>31,460,476</b>	<b>3,228,687</b>	<b>48,353,182</b>	<b>48,353,182</b>

# Selected explanatory notes for the abridged notes to the consolidated financial statements as at 30 June 2019

## 1. General

Medios AG (hereinafter also referred to as "Company", "Medios" and, in connection with its subsidiaries, "Medios Group") as the parent company is a public limited company registered in Germany. The shares of the company are listed on the Regulated Market of the Frankfurt Stock Exchange (General Standard). The shares are also listed on the regulated market of the Hamburg Stock Exchange and are permitted for trade in the free market of the Düsseldorf and Stuttgart Stock Exchanges. Medios AG is the parent company of the Group. It is registered at the District Court of Hamburg under number HRB 70680.

The company's headquarters are located in Hamburg. Its business address is Friedrichstraße 113a, 10117 Berlin, Germany.

The abridged consolidated interim financial statements are presented in euros (EUR), as all Group transactions are made in this currency and the euro is therefore the Group's functional currency. Unless otherwise specified, all figures are stated in thousands of euros (KEUR). Please note that due to commercial rounding, the use of rounded sums and percentages may result in differences, including within individual tables. This also affects the totals and interim totals shown in the consolidated interim financial statements.

The consolidated income statement is prepared according to the total cost procedure. The financial year of the Company and the companies included in the scope of consolidation is the calendar year. The abridged consolidated interim financial statements relate to the period from 1 January to 30 June 2019 with the corresponding previous year comparison.

## 2. Business activity

As a management and service holding company, Medios AG has the central management function over the Medios Group. It controls the business activity of the Group, defines inter alia the Group's operational planning and monitors compliance with the latter.

The 100% subsidiary Medios Pharma GmbH is a pharmaceutical wholesale company with permission to operate under Section 52a of the German Medicinal Products Act (Arzneimittelgesetz, AMG) and supplies the customers of Medios with specialty pharmaceuticals according to market and need. This work is primarily focused on oncology, autoimmunology and infectious diseases. Medios Pharma is a significant expert in the market with a comprehensive network and many years of experience.

The 100% subsidiary Medios Manufaktur GmbH is a producer of specialty pharmaceuticals in Germany. With their products and supplementary services for pharmacies, they cover the most important parts of the supply chain. The preparation of every single drug complies with the highest international quality standards (GMP). This work is focused inter alia on infusion solutions for the oncology market.

The 100% subsidiary Medios Individual GmbH specialises in the production of patient-specific antiviral and antibiotic solutions, the production of parenteral nutrition solutions and the manufacturing of ophthalmological preparations. Medios Individual also offers pharmacies supplementary services. The production of drugs and solutions complies with the highest international quality standards (GMP).

The 100% subsidiary Medios Digital GmbH is the internal system service provider of the Medios Group and develops software and infrastructure solutions. This specifically involves logistics processes such as purchasing, warehousing and sales as well as optimised trading processes with integrated interfaces with our customers. The focus of our work is the development and implementation of software solutions for Medios Pharma GmbH.

## 3. Principles for preparing the abridged consolidated interim financial statements

The abridged consolidated interim financial statements for the period from 1 January to 30 June 2019 were prepared in accordance with IAS 34 "Interim Financial Reporting". These abridged consolidated interim financial statements do not contain all the information required for financial statements of a financial year and should be read in connection with the consolidated financial statements as at 31 December 2018.

The accounting and valuation methods used to prepare the abridged consolidated interim financial statements are the same as those applied to the last consolidated financial statements as at 31 December 2018.

The consolidated interim financial statements dated 30 June 2019 are drawn up according to the IFRS as applicable within the EU. All standards that must be applied were therefore considered. There was no early application of the standards. The initial application of standards and interpretations did not produce any effects on the accounting policies and the representation of the Group's net assets, financial position and results of operations.

With effect from 1 January 2019, Medios Group will apply IFRS 16 "Leases" for the first time. The new regulation governs the recording, assessment, presentation and information concerning leasing arrangements. From 1 January 2019 onwards, IFRS 16 must be applied. The new leasing standard replaces the previous regulations of IAS 17 – Leasing arrangements. In contrast to the previous regulations, it provides for the recording of the rights of use and lease liabilities resulting from leases in the balance sheet for the lessee. There is therefore no longer any difference between off-balance sheet operating leases and on-balance sheet finance leases. The lease liability to be recorded under liabilities is determined as the cash value of the payments most likely to be made to the lessee. It shall be updated according to the effective interest method. The right of use to the underlying asset to be recorded in return must be recorded at its acquisition cost at the start of the lease.

In addition to lease payments, any initial direct costs of the lessee and restoration costs must be included in its determination. The capitalised right of use must be amortised as scheduled and be checked for impairment in the event of any relevant indications.

The company shall apply the new accounting standard to leasing arrangements with a residual term of more than one year as at 1 January 2019 according to the modified retrospective method. The previous year's values are not adjusted. Medios Group shall not make use of the voting right not to account for low-value and current leasing arrangements but shall continue to record them under operating expenses. Property rent and vehicles are in particular the subject of the leases that have been concluded.

The following leasing rights of use have been accounted for as at 30 June 2019:	EUR 1 million
Real estate	2.26
Technical equipment and machines	0.08
<b>Total</b>	<b>2.34</b>

Amortisations on leasing rights of use are comprised as follows in the year under review:	EUR 1 million
Real estate	0.29
Technical equipment and machines	0.02
<b>Total</b>	<b>0.32</b>

Rights of use of EUR 1.43m were recorded in the opening balance as at 1 January 2019. Leasing liabilities of the same amount were recorded on the liabilities side in the opening balance. The first-time application did not affect equity.

The reconciliation of the future minimum lease payments from operating leasing arrangements reported as at 31 December 2018 pursuant to IAS 17 with the lease liabilities accounted for as at 1 January 2019 pursuant to IFRS 16 are shown below:

	EUR 1 million
Future minimum lease payments from operating leasing arrangements as at 31 December 2018	1.57
Leases concluded in the 2018 financial year with leasing arrangements beginning in the 2019 financial year	-0.01
Current leasing arrangements	-0.03
<b>Additional gross leasing arrangements</b>	<b>1.53</b>
Discounting	-0.10
<b>Lease liabilities as at 1 January 2019</b>	<b>1.43</b>

Non-recorded leases amount to EUR 0.3m due to terms of less than one year or lower lease payments.

A weighted average incremental borrowing rate of 3% was used as a basis for the determination.

As a result of the change in the recording of expenses from operating leasing arrangements in the cash flow statement, there was an improvement in operating cash flow of EUR 0.30m in the first half of 2019. The cash flow from the financing activity decreased accordingly.

#### 4. Scope of consolidation

The present abridged consolidated interim financial statements as at 30 June 2019 include the following subsidiaries in addition to Medios AG:

- Medios Pharma GmbH, Berlin (100%)
- Medios Manufaktur GmbH, Berlin (100%)
- Medios Digital GmbH, Berlin (100%)
- Medios Individual GmbH, Berlin (100%)

All subsidiaries controlled by Medios AG have been fully consolidated provided they were material to the Group's net assets, financial position and results of operations.

#### 5. Significant events in the first half of 2019

→ See management report

## 6. Remarks on the consolidated cash flow statement

The cash flow statement shows how the cash of the Group changed over the course of the reporting year through inflows and outflows of cash. A distinction is made between cash flows from operating, investing and financing activities. The cash in the cash flow statement consists exclusively of freely available cash.

## 7. Segment reporting

As at 30 June 2019, the Medios Group is divided into the segments "Drug Supply", "Patient-Specific Therapies" and "Services". The segments differ in terms of their service profile. Transactions between segments are presented in accordance with IFRS accounting principles. An aggregation of business segments was not carried out. The activities of Medios Group only extend to Germany and the EU. The business activity of the segments can be broken down as follows:

- Drug Supply focusing on speciality pharmaceutical medicinal products, summarised as a business in Medios Pharma GmbH. The focus on speciality pharmaceuticals means that as a rule it trades almost exclusively in expensive medicinal products for chronic and/or rare diseases. These are approximately 1,000 out of 100,000 various pharmaceutical products available in Germany. With an extensive range, Medios stands out from the medicinal product wholesale trade with this consistent and clear focus.
- Patient-Specific Therapies comprise the manufacture of medications on behalf of pharmacies, established in the companies Medios Manufaktur GmbH and Medios Individual GmbH. Patient-specific therapies include, for example, infusions constituted and produced on the basis of individual symptoms and individual parameters such as body weight and body surface. The batch for each manufactured formulation is therefore always precisely one. They are manufactured to the highest possible standards, as a rule in line with GMP (Good Manufacturing Practice).
- The third segment, Services, includes all other Group activities, including Medios Group holding activities and, in particular, tasks relevant to the capital market and software and infrastructure solutions for the Medios Group.

Revenue and segment results for the first half of 2019 are broken down as follows:

IN KEUR	Drug Supply		Patient-Specific Therapies	
	1st Half of 2019	1st Half of 2018	1st Half of 2019	1st Half of 2018
Revenue – external	204,277	130,237	24,159	15,775
Revenue – internal	10,254	4,681	4,512	10,378
<b>Total segment revenue</b>	<b>214,531</b>	<b>134,918</b>	<b>28,671</b>	<b>26,154</b>
EBITDA	5,256	4,598	2,602	416
EBITDA before special effects	5,362	4,598	2,803	1,011
Depreciation and amortisation	185	49	698	108
EBT before special effects	5,083	4,486	2,327	928
EBT	4,977	4,486	1,822	284

Services		Reconciliation		Elimination		Group	
1st Half of 2019	1st Half of 2018	1st Half of 2019	1st Half of 2018	1st Half of 2019	1st Half of 2018	1st Half of 2019	1st Half of 2018
70	57		-1,354			228,506	144,716
1,957	1,171			-16,723	-16,230	0	0
2,027	1,228		-1,354	-16,723	-16,230	228,506	144,716
-779	-1,693		-22	-9		7,070	3,299
-444	-543		-22	-9		7,712	5,044
222	126		77			1,104	360
-554	-592		-99	-9		6,847	4,723
-889	-1,743		-99	-9		5,901	2,928



## Other information

## 8. Contingent liabilities and other financial liabilities

As at 30 June 2019, there are no significant contingent liabilities or legal disputes. There are significant financial obligations in connection with deliveries and services.

## 9. Transactions with related companies and parties

Related companies and parties within the meaning of IAS 24 are, inter alia, companies and persons where one of the parties directly or indirectly has the means of controlling or exerting significant influence over the other party. Detailed information on related companies and parties in key positions is provided in the notes to the consolidated financial statements for 2018.

Business transactions with related companies and parties relate in particular to trade in goods and services, purchase price obligations, as well as management and holding activities.

The following table shows significant transactions with related companies and parties in the reporting period:

	Income 01/01-30/06/2019	Expenditure 01/01-30/06/2019	Receivables 30/06/2019	Liabilities 30/06/2019
	KEUR	KEUR	KEUR	KEUR
Spezial-Pharma Manfred Schneider e. K.	0	26	0	0
Tangaroa Management GmbH [later mediosmanagement GmbH]	0	22	2	0
<b>Total</b>	<b>0</b>	<b>48</b>	<b>2</b>	<b>0</b>

## 10. Earnings per share

Earnings per share are determined as a ratio of the consolidated net income attributable to the shareholders of Medios AG and the weighted average number of shares in circulation in the reporting year.

Calculation of earnings per share	30/06/2019	30/06/2019
Share in consolidated profit attributable to the shareholders of the parent company (in KEUR)	3,971	1,526
Weighted average number of ordinary shares (in thousands of units)	14,564	13,664
Undiluted earnings per share (in EUR)	0,27	0,11
Diluted earnings per share (in EUR)	0,27	0,11

## 11. Events after the balance sheet date

Medios AG successfully held the Annual General Meeting 2019 on 10 July 2019. All resolutions on the agenda items were passed with a clear majority. Overall, around 64% of the share capital was represented. Among the items on the agenda were the discharge of the members of the Management and Supervisory Boards, the choice of auditor as well as the creation of new authorised and new conditional capital for 2019. In addition, shareholders approved a profit and loss transfer agreement with Medios Analytics GmbH. The individual voting results for the agenda items are available on the website of Medios AG.

## Statement from the company's legal representatives

We hereby declare that to the best of our knowledge, a true and fair view of the net assets, financial position and results of operations of the Group is provided in accordance with the applicable accounting standards for half-yearly financial reporting in the consolidated interim financial statements and in the interim Group management report and that business performance including the business results and the situation of the Group are presented in a way that gives a true and fair view of the actual opportunities and risks of the expected performance of the Group during the remainder of the financial year.

Berlin, August 2019

**Manfred Scheider**  
(Chairman of the Executive Board)

**Matthias Gärtner**  
(Executive Board)


**Mi-Young Miehler**  
(Executive Board)

**Christoph Prußbeit**  
(Executive Board)

# Shares

Share	
Headquarter	Hamburg
Business address	Berlin
Share capital	EUR 14,564,019
Number of shares	14,564,019 no-par value bearer shares
Current rate	EUR 17,00 (as of 30 August 2019)
Market capitalization	EUR 248 m
WKN / ISIN	A1MMCC / DE000A1MMCC8
Market segment	Regulated market (Frankfurt) Regulated market (Hamburg)
Shareholder structure	
<b>Manfred Schneider</b>	<b>40.52%</b>
incl. attribution of Tangaroa Management GmbH (formally mediosmanagement GmbH) 8.28% direct, 32.24% addition	
<b>CRANACH PHARMA GmbH</b>	<b>3.43%</b>
Martin Hesse	
<b>Freefloat*</b>	<b>56.05%</b>
thereof 3.70% Claudia Neuhaus	

\* as defined by Deutsche Börse AG Link to Deutsche Börse AG









# Imprint

**MEDIOS AG**  
Friedrichstr. 113a  
10117 Berlin

Phone: +49 (0) 30 232 566 8-00  
Fax: +49 (0) 30 232 566 8-01

ir@medios.ag  
www.medios.ag

**Supervisory Board**  
Dr. Yann Samson (Chairman)  
Joachim Messner (Deputy chairman)  
Klaus J. Buß (Member)

**Executive Board**  
Manfred Schneider (CEO)  
Matthias Gärtner (CFO)  
Mi-Young Miehler (COO)  
Christoph Prußeit (CIO)

Registered in the commercial register  
of the district court Hamburg under HRB 70680

**Concept**  
Medios AG

**Investor Relations**  
Jörn Ney

**Layout**  
Gina Mönch, Art Direction, Berlin

© Medios AG 2019

